Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial
This study investigated the effects of oleoylethanolamide (OEA) supplementation on the expression levels of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α and CEBP-β genes and serum neuregulin 4 (NRG4) levels in patients with non-alcoholic fatty liver diseases (NAFLD). Sixty obese patients with NAFLD were equa...
Gespeichert in:
| Veröffentlicht in: | Clinical nutrition ESPEN 2023-12, Vol.58, p.311-319 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 319 |
|---|---|
| container_issue | |
| container_start_page | 311 |
| container_title | Clinical nutrition ESPEN |
| container_volume | 58 |
| creator | Tutunchi, Helda Ebrahimi-Mameghani, Mehrangiz Hosseinzadeh-Attar, Mohammad Javad Roshanravan, Neda Mobasseri, Majid Najafipour, Farzad Naeini, Fatemeh Naghshi, Sina Asghari, Samira Akbarzadeh, Moloud Soleimanzadeh, Hamid Ostadrahimi, Alireza |
| description | This study investigated the effects of oleoylethanolamide (OEA) supplementation on the expression levels of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α and CEBP-β genes and serum neuregulin 4 (NRG4) levels in patients with non-alcoholic fatty liver diseases (NAFLD).
Sixty obese patients with NAFLD were equally allocated into either OEA or placebo group for 12 weeks. The mRNA expression levels of genes were determined using the reverse transcription polymerase chain reaction (RT-PCR) technique. Serum NRG4 level was also assessed using an enzyme-linked immunosorbent assay (ELISA) kit.
At the endpoint, mRNA expression levels of SIRT1(p = 0.001), PGC-1α (p = 0.011) and AMPK (p = 0.019) were significantly higher in the OEA group compared to placebo group. However, no significant differences were observed in the expression levels of PPAR-γ, CEBP-α and CEBP-β between the two groups. Serum NRG4 levels significantly increased in the OEA group compared with the placebo group after controlling for confounders (p = 0.027). In the OEA group, significant relationships were found between percent of changes in the expression levels of the SIRT1, AMPK and PGC-1α as well as serum NRG4 level with percent of changes in some anthropometric measures. Moreover, in the intervention group, percent of changes in high-density lipoprotein cholesterol was positively correlated with percent of changes in the expression levels of the SIRT1 and AMPK. While, percent of changes in triglyceride was inversely correlated with percent of changes in the expression levels of SIRT1.
OEA could beneficially affect expression levels of some lipid metabolism-related genes and serum NRG4 level.
IRCT20090609002017N32”. |
| doi_str_mv | 10.1016/j.clnesp.2023.10.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2899374558</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S240545772302171X</els_id><sourcerecordid>2899374558</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-449ca905b15a37ea59f4cb623b52aa300334a161f698b3ad3b98e77b71f591af3</originalsourceid><addsrcrecordid>eNp9kcGKFDEQhhtR3GXdNxDJ0UuPSSeZ7ngQlmVdhUVB9Byq0xUnQzppk8ys4xv6VmacVTwJgRQ_f31V1N80zxldMcrWr7Yr4wPmZdXRjldpRRl_1Jx3gspWyL5__E991lzmvKW09iklGH3anPGByp527Lz5eWMtmpJJtCR6jAePZQMhepjdhCTvlsXjjKFAcTGQ-soGCX5fEub8W7HEu8VNZMYCY_Quz21CDwUn8hXrjgTCRDKm3Uw-fLoVxOMefSYukKUyKzmTe1c2JMTQgjdxUxmGWCjlUMl7TGRyGSHja3JFUoXF2f2ocBNDSdH7WpbkwD9rnljwGS8f_ovmy9ubz9fv2ruPt--vr-5aw2VfWiGUAUXlyCTwHkEqK8y47vgoOwBOKecC2JrZtRpGDhMf1YB9P_bMSsXA8ovm5Ym7pPhth7no2WWD3kPAuMu6G5TivZByqFZxspoUc05o9ZLcDOmgGdXHHPVWn3LUxxyPas2xtr14mLAbZ5z-Nv1JrRrenAz1kLh3mHQ29ZIGJ5dqmHqK7v8TfgFW6LWh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2899374558</pqid></control><display><type>article</type><title>Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Tutunchi, Helda ; Ebrahimi-Mameghani, Mehrangiz ; Hosseinzadeh-Attar, Mohammad Javad ; Roshanravan, Neda ; Mobasseri, Majid ; Najafipour, Farzad ; Naeini, Fatemeh ; Naghshi, Sina ; Asghari, Samira ; Akbarzadeh, Moloud ; Soleimanzadeh, Hamid ; Ostadrahimi, Alireza</creator><creatorcontrib>Tutunchi, Helda ; Ebrahimi-Mameghani, Mehrangiz ; Hosseinzadeh-Attar, Mohammad Javad ; Roshanravan, Neda ; Mobasseri, Majid ; Najafipour, Farzad ; Naeini, Fatemeh ; Naghshi, Sina ; Asghari, Samira ; Akbarzadeh, Moloud ; Soleimanzadeh, Hamid ; Ostadrahimi, Alireza</creatorcontrib><description>This study investigated the effects of oleoylethanolamide (OEA) supplementation on the expression levels of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α and CEBP-β genes and serum neuregulin 4 (NRG4) levels in patients with non-alcoholic fatty liver diseases (NAFLD).
Sixty obese patients with NAFLD were equally allocated into either OEA or placebo group for 12 weeks. The mRNA expression levels of genes were determined using the reverse transcription polymerase chain reaction (RT-PCR) technique. Serum NRG4 level was also assessed using an enzyme-linked immunosorbent assay (ELISA) kit.
At the endpoint, mRNA expression levels of SIRT1(p = 0.001), PGC-1α (p = 0.011) and AMPK (p = 0.019) were significantly higher in the OEA group compared to placebo group. However, no significant differences were observed in the expression levels of PPAR-γ, CEBP-α and CEBP-β between the two groups. Serum NRG4 levels significantly increased in the OEA group compared with the placebo group after controlling for confounders (p = 0.027). In the OEA group, significant relationships were found between percent of changes in the expression levels of the SIRT1, AMPK and PGC-1α as well as serum NRG4 level with percent of changes in some anthropometric measures. Moreover, in the intervention group, percent of changes in high-density lipoprotein cholesterol was positively correlated with percent of changes in the expression levels of the SIRT1 and AMPK. While, percent of changes in triglyceride was inversely correlated with percent of changes in the expression levels of SIRT1.
OEA could beneficially affect expression levels of some lipid metabolism-related genes and serum NRG4 level.
IRCT20090609002017N32”.</description><identifier>ISSN: 2405-4577</identifier><identifier>EISSN: 2405-4577</identifier><identifier>DOI: 10.1016/j.clnesp.2023.10.013</identifier><identifier>PMID: 38057021</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>AMP-Activated Protein Kinases - genetics ; AMP-Activated Protein Kinases - metabolism ; Dietary Supplements ; Humans ; Iran ; Lipid Metabolism - genetics ; Lipid metabolism-related genes ; Neuregulins - metabolism ; Neuregulins - therapeutic use ; Non-alcoholic fatty liver disease ; Non-alcoholic Fatty Liver Disease - drug therapy ; Non-alcoholic Fatty Liver Disease - genetics ; NRG4 ; Oleoylethanolamide ; Peroxisome Proliferator-Activated Receptors - metabolism ; Peroxisome Proliferator-Activated Receptors - therapeutic use ; RNA, Messenger - metabolism ; RNA, Messenger - therapeutic use ; Sirtuin 1 - genetics ; Sirtuin 1 - metabolism ; Sirtuin 1 - therapeutic use ; Weight loss diet</subject><ispartof>Clinical nutrition ESPEN, 2023-12, Vol.58, p.311-319</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-449ca905b15a37ea59f4cb623b52aa300334a161f698b3ad3b98e77b71f591af3</cites><orcidid>0000-0002-6073-7624</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38057021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tutunchi, Helda</creatorcontrib><creatorcontrib>Ebrahimi-Mameghani, Mehrangiz</creatorcontrib><creatorcontrib>Hosseinzadeh-Attar, Mohammad Javad</creatorcontrib><creatorcontrib>Roshanravan, Neda</creatorcontrib><creatorcontrib>Mobasseri, Majid</creatorcontrib><creatorcontrib>Najafipour, Farzad</creatorcontrib><creatorcontrib>Naeini, Fatemeh</creatorcontrib><creatorcontrib>Naghshi, Sina</creatorcontrib><creatorcontrib>Asghari, Samira</creatorcontrib><creatorcontrib>Akbarzadeh, Moloud</creatorcontrib><creatorcontrib>Soleimanzadeh, Hamid</creatorcontrib><creatorcontrib>Ostadrahimi, Alireza</creatorcontrib><title>Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial</title><title>Clinical nutrition ESPEN</title><addtitle>Clin Nutr ESPEN</addtitle><description>This study investigated the effects of oleoylethanolamide (OEA) supplementation on the expression levels of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α and CEBP-β genes and serum neuregulin 4 (NRG4) levels in patients with non-alcoholic fatty liver diseases (NAFLD).
Sixty obese patients with NAFLD were equally allocated into either OEA or placebo group for 12 weeks. The mRNA expression levels of genes were determined using the reverse transcription polymerase chain reaction (RT-PCR) technique. Serum NRG4 level was also assessed using an enzyme-linked immunosorbent assay (ELISA) kit.
At the endpoint, mRNA expression levels of SIRT1(p = 0.001), PGC-1α (p = 0.011) and AMPK (p = 0.019) were significantly higher in the OEA group compared to placebo group. However, no significant differences were observed in the expression levels of PPAR-γ, CEBP-α and CEBP-β between the two groups. Serum NRG4 levels significantly increased in the OEA group compared with the placebo group after controlling for confounders (p = 0.027). In the OEA group, significant relationships were found between percent of changes in the expression levels of the SIRT1, AMPK and PGC-1α as well as serum NRG4 level with percent of changes in some anthropometric measures. Moreover, in the intervention group, percent of changes in high-density lipoprotein cholesterol was positively correlated with percent of changes in the expression levels of the SIRT1 and AMPK. While, percent of changes in triglyceride was inversely correlated with percent of changes in the expression levels of SIRT1.
OEA could beneficially affect expression levels of some lipid metabolism-related genes and serum NRG4 level.
IRCT20090609002017N32”.</description><subject>AMP-Activated Protein Kinases - genetics</subject><subject>AMP-Activated Protein Kinases - metabolism</subject><subject>Dietary Supplements</subject><subject>Humans</subject><subject>Iran</subject><subject>Lipid Metabolism - genetics</subject><subject>Lipid metabolism-related genes</subject><subject>Neuregulins - metabolism</subject><subject>Neuregulins - therapeutic use</subject><subject>Non-alcoholic fatty liver disease</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Non-alcoholic Fatty Liver Disease - genetics</subject><subject>NRG4</subject><subject>Oleoylethanolamide</subject><subject>Peroxisome Proliferator-Activated Receptors - metabolism</subject><subject>Peroxisome Proliferator-Activated Receptors - therapeutic use</subject><subject>RNA, Messenger - metabolism</subject><subject>RNA, Messenger - therapeutic use</subject><subject>Sirtuin 1 - genetics</subject><subject>Sirtuin 1 - metabolism</subject><subject>Sirtuin 1 - therapeutic use</subject><subject>Weight loss diet</subject><issn>2405-4577</issn><issn>2405-4577</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcGKFDEQhhtR3GXdNxDJ0UuPSSeZ7ngQlmVdhUVB9Byq0xUnQzppk8ys4xv6VmacVTwJgRQ_f31V1N80zxldMcrWr7Yr4wPmZdXRjldpRRl_1Jx3gspWyL5__E991lzmvKW09iklGH3anPGByp527Lz5eWMtmpJJtCR6jAePZQMhepjdhCTvlsXjjKFAcTGQ-soGCX5fEub8W7HEu8VNZMYCY_Quz21CDwUn8hXrjgTCRDKm3Uw-fLoVxOMefSYukKUyKzmTe1c2JMTQgjdxUxmGWCjlUMl7TGRyGSHja3JFUoXF2f2ocBNDSdH7WpbkwD9rnljwGS8f_ovmy9ubz9fv2ruPt--vr-5aw2VfWiGUAUXlyCTwHkEqK8y47vgoOwBOKecC2JrZtRpGDhMf1YB9P_bMSsXA8ovm5Ym7pPhth7no2WWD3kPAuMu6G5TivZByqFZxspoUc05o9ZLcDOmgGdXHHPVWn3LUxxyPas2xtr14mLAbZ5z-Nv1JrRrenAz1kLh3mHQ29ZIGJ5dqmHqK7v8TfgFW6LWh</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Tutunchi, Helda</creator><creator>Ebrahimi-Mameghani, Mehrangiz</creator><creator>Hosseinzadeh-Attar, Mohammad Javad</creator><creator>Roshanravan, Neda</creator><creator>Mobasseri, Majid</creator><creator>Najafipour, Farzad</creator><creator>Naeini, Fatemeh</creator><creator>Naghshi, Sina</creator><creator>Asghari, Samira</creator><creator>Akbarzadeh, Moloud</creator><creator>Soleimanzadeh, Hamid</creator><creator>Ostadrahimi, Alireza</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6073-7624</orcidid></search><sort><creationdate>202312</creationdate><title>Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial</title><author>Tutunchi, Helda ; Ebrahimi-Mameghani, Mehrangiz ; Hosseinzadeh-Attar, Mohammad Javad ; Roshanravan, Neda ; Mobasseri, Majid ; Najafipour, Farzad ; Naeini, Fatemeh ; Naghshi, Sina ; Asghari, Samira ; Akbarzadeh, Moloud ; Soleimanzadeh, Hamid ; Ostadrahimi, Alireza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-449ca905b15a37ea59f4cb623b52aa300334a161f698b3ad3b98e77b71f591af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>AMP-Activated Protein Kinases - genetics</topic><topic>AMP-Activated Protein Kinases - metabolism</topic><topic>Dietary Supplements</topic><topic>Humans</topic><topic>Iran</topic><topic>Lipid Metabolism - genetics</topic><topic>Lipid metabolism-related genes</topic><topic>Neuregulins - metabolism</topic><topic>Neuregulins - therapeutic use</topic><topic>Non-alcoholic fatty liver disease</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Non-alcoholic Fatty Liver Disease - genetics</topic><topic>NRG4</topic><topic>Oleoylethanolamide</topic><topic>Peroxisome Proliferator-Activated Receptors - metabolism</topic><topic>Peroxisome Proliferator-Activated Receptors - therapeutic use</topic><topic>RNA, Messenger - metabolism</topic><topic>RNA, Messenger - therapeutic use</topic><topic>Sirtuin 1 - genetics</topic><topic>Sirtuin 1 - metabolism</topic><topic>Sirtuin 1 - therapeutic use</topic><topic>Weight loss diet</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tutunchi, Helda</creatorcontrib><creatorcontrib>Ebrahimi-Mameghani, Mehrangiz</creatorcontrib><creatorcontrib>Hosseinzadeh-Attar, Mohammad Javad</creatorcontrib><creatorcontrib>Roshanravan, Neda</creatorcontrib><creatorcontrib>Mobasseri, Majid</creatorcontrib><creatorcontrib>Najafipour, Farzad</creatorcontrib><creatorcontrib>Naeini, Fatemeh</creatorcontrib><creatorcontrib>Naghshi, Sina</creatorcontrib><creatorcontrib>Asghari, Samira</creatorcontrib><creatorcontrib>Akbarzadeh, Moloud</creatorcontrib><creatorcontrib>Soleimanzadeh, Hamid</creatorcontrib><creatorcontrib>Ostadrahimi, Alireza</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nutrition ESPEN</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tutunchi, Helda</au><au>Ebrahimi-Mameghani, Mehrangiz</au><au>Hosseinzadeh-Attar, Mohammad Javad</au><au>Roshanravan, Neda</au><au>Mobasseri, Majid</au><au>Najafipour, Farzad</au><au>Naeini, Fatemeh</au><au>Naghshi, Sina</au><au>Asghari, Samira</au><au>Akbarzadeh, Moloud</au><au>Soleimanzadeh, Hamid</au><au>Ostadrahimi, Alireza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial</atitle><jtitle>Clinical nutrition ESPEN</jtitle><addtitle>Clin Nutr ESPEN</addtitle><date>2023-12</date><risdate>2023</risdate><volume>58</volume><spage>311</spage><epage>319</epage><pages>311-319</pages><issn>2405-4577</issn><eissn>2405-4577</eissn><abstract>This study investigated the effects of oleoylethanolamide (OEA) supplementation on the expression levels of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α and CEBP-β genes and serum neuregulin 4 (NRG4) levels in patients with non-alcoholic fatty liver diseases (NAFLD).
Sixty obese patients with NAFLD were equally allocated into either OEA or placebo group for 12 weeks. The mRNA expression levels of genes were determined using the reverse transcription polymerase chain reaction (RT-PCR) technique. Serum NRG4 level was also assessed using an enzyme-linked immunosorbent assay (ELISA) kit.
At the endpoint, mRNA expression levels of SIRT1(p = 0.001), PGC-1α (p = 0.011) and AMPK (p = 0.019) were significantly higher in the OEA group compared to placebo group. However, no significant differences were observed in the expression levels of PPAR-γ, CEBP-α and CEBP-β between the two groups. Serum NRG4 levels significantly increased in the OEA group compared with the placebo group after controlling for confounders (p = 0.027). In the OEA group, significant relationships were found between percent of changes in the expression levels of the SIRT1, AMPK and PGC-1α as well as serum NRG4 level with percent of changes in some anthropometric measures. Moreover, in the intervention group, percent of changes in high-density lipoprotein cholesterol was positively correlated with percent of changes in the expression levels of the SIRT1 and AMPK. While, percent of changes in triglyceride was inversely correlated with percent of changes in the expression levels of SIRT1.
OEA could beneficially affect expression levels of some lipid metabolism-related genes and serum NRG4 level.
IRCT20090609002017N32”.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38057021</pmid><doi>10.1016/j.clnesp.2023.10.013</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6073-7624</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2405-4577 |
| ispartof | Clinical nutrition ESPEN, 2023-12, Vol.58, p.311-319 |
| issn | 2405-4577 2405-4577 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2899374558 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | AMP-Activated Protein Kinases - genetics AMP-Activated Protein Kinases - metabolism Dietary Supplements Humans Iran Lipid Metabolism - genetics Lipid metabolism-related genes Neuregulins - metabolism Neuregulins - therapeutic use Non-alcoholic fatty liver disease Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - genetics NRG4 Oleoylethanolamide Peroxisome Proliferator-Activated Receptors - metabolism Peroxisome Proliferator-Activated Receptors - therapeutic use RNA, Messenger - metabolism RNA, Messenger - therapeutic use Sirtuin 1 - genetics Sirtuin 1 - metabolism Sirtuin 1 - therapeutic use Weight loss diet |
| title | Effects of oleoylethanolamide supplementation on the expression of lipid metabolism-related genes and serum NRG4 levels in patients with non-alcoholic fatty liver disease: A randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T18%3A38%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20oleoylethanolamide%20supplementation%20on%20the%20expression%20of%20lipid%20metabolism-related%20genes%20and%20serum%20NRG4%20levels%20in%20patients%20with%20non-alcoholic%20fatty%20liver%20disease:%20A%20randomized%20controlled%20trial&rft.jtitle=Clinical%20nutrition%20ESPEN&rft.au=Tutunchi,%20Helda&rft.date=2023-12&rft.volume=58&rft.spage=311&rft.epage=319&rft.pages=311-319&rft.issn=2405-4577&rft.eissn=2405-4577&rft_id=info:doi/10.1016/j.clnesp.2023.10.013&rft_dat=%3Cproquest_cross%3E2899374558%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2899374558&rft_id=info:pmid/38057021&rft_els_id=S240545772302171X&rfr_iscdi=true |